Johnson & Johnson welcomes the New Zealand
Government’s announcement to dedicate an additional $604m
to bring much needed innovative cancer medicines to New
Zealand patients.
“There is currently a significant
unmet need in a range of cancer treatment options,” Hayden
Paul, Commercial Lead, Johnson & Johnson New Zealand
said.
“J&J believes this week’s announcement
is a positive sign for the thousands of patients who are
waiting for access to medicines. We trust the Government
will act swiftly to finalise access to these new medicines
for cancer treatment.
“New Zealand has long been a
challenging environment for medicines access and for
medicines businesses. This announcement offers the
possibility for increased business confidence and could
support increased investment and jobs for New Zealand’s
future.”
Advertisement – scroll to continue reading
© Scoop Media
Advertisement – scroll to continue reading